
- Trade $0 commission stocks & ETFs with as little as $1
- Earn up to $300 with qualifying deposits
- Discover new opportunities with Opto's AI-driven thematic investing system
- Theme and ETF screener
Affimed is a biotechnology business based in the US. Affimed shares (AFMD) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.06 – an increase of 0.95% over the previous week. Affimed employs 76 staff and has a trailing 12-month revenue of around $7.4 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Latest market close | $1.06 |
---|---|
52-week range | $0.92 - $8.95 |
50-day moving average | $1.44 |
200-day moving average | $3.68 |
Wall St. target price | $13.41 |
PE ratio | N/A |
Dividend yield | N/A |
Earnings per share (TTM) | $-4.72 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.06 from 2025-02-13
1 week (2025-02-07) | 0.95% |
---|---|
1 month (2025-01-16) | -1.85% |
3 months (2024-11-15) | -69.54% |
6 months (2024-08-16) | -73.37% |
1 year (2024-02-15) | 82.88% |
---|---|
2 years (2023-02-15) | -90.00% |
3 years (2022-02-15) | 45.5 |
5 years (2020-02-14) | 25.3 |
Revenue TTM | $7.4 million |
---|---|
Gross profit TTM | $7.4 million |
Return on assets TTM | -49.31% |
Return on equity TTM | -124.08% |
Profit margin | 0% |
Book value | $3.85 |
Market Capitalization | $17.4 million |
TTM: trailing 12 months
We're not expecting Affimed to pay a dividend over the next 12 months.
Affimed's shares were split on a 1:10 basis on 10 March 2024 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Affimed shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Affimed shares which in turn could have impacted Affimed's share price.
Over the last 12 months, Affimed's shares have ranged in value from as little as $0.92 up to $8.95. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Affimed's is 2.098. This would suggest that Affimed's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Affimed N. V. , a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers.
Spot dogecoin ETFs might soon be approved. Here’s how to invest if and when they become available to trade.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.